Realizing the Promise of IL-2 Therapies with AI

Aron Knickerbocker, president and CEO of Aulos Bioscience, discusses the potential for IL-2 therapies to treat solid tumors, the limits of today’s IL-2 therapies, and the AI-based design behind its experimental IL-2 therapy in development.